Thrombolytic Therapy

Consultative Hemostasis and Thrombosis

Volumn , Issue , 2007, Pages 491-501

  Marder, Victor J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61449207900     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141602401-9.10028-8     Document Type: Chapter

References (124)

1. M Verstraete (1978) Biochemical and clinical aspects of thrombolysis. Semin Hematol 15 35.
2. VJ Marder (1979) The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 90 802.
3. VJ Marder and S Sherry (1988) Thrombolytic therapy: Current status. N Engl J Med 18 1512.
4. ML Simoons and AE Arnold (1993) Tailored thrombolytic therapy: A perspective. Circulation 88 2556.
5. VJ Marder (2006) Foundations of thrombolytic therapy. RW Colman, VJ Marder, AW Clowes, et al., (Eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice 5th edition Philadelphia: Lippincott, Williams & Wilkins 1739.
6. DH Staniforth, RAG Smith and M Hibbs (1983) Streptokinase and anisoylated streptokinase plasminogen complex: Their action on haemostasis in human volunteers. Eur J Clin Pharmacol 24 751.
7. C Bode, RW Smalling, G Berg, et al. (1996) Randomized comparison of coronary thrombolysis achieved with double‐bolus reteplase (recombinant plasminogen activator) and front‐loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 94 891.
8. NB Modi, S Eppler, J Breed, et al. (1998) Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK‐t‐PA, in patients with acute myocardial infarction. Thromb Haemost 79 134.
9. C Korninger, O Matsuo, R Suy, et al. (1982) Thrombolysis with human extrinsic (tissue‐type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 69 573.
10. CP Cannon, CH McCabe, CM Gibson, et al. (1997) TNK‐tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose‐ranging trial. Circulation 95 351.
11. VJ Marder and D Stewart (2002) Towards safer thrombolytic therapy. Semin Hematol 39 206.
12. JL Ambrus, CM Ambrus, N Back, et al. (1957) Clinical and experimental studies on fibrinolytic enzymes. Ann N Y Acad Sci 68 97.
13. VJ Marder, K Landskroner, V Novokhatny, et al. (2001) Plasmin induces local thrombolysis without causing hemorrhage: A comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86 739.
14. V Novokhatny, K Taylor and TP Zimmerman (2003) Thrombolytic potency of acid‐stabilized plasmin: Superiority over tissue‐type plasminogen activator in an in vitro model of catheter‐assisted thrombolysis. J Thromb Haemost 1 1034-1041.
15. N Nagai, M De Mol, B Van Hoef, et al. (2001) Depletion of circulating α2‐antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood 97 3086.
16. CF Toombs (2001) Alfimeprase: Pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 31 141.
17. VV Novokhatny, GJ Jesmok, KA Landskroner, et al. (2004) Locally delivered plasmin: Why should it be superior to plasminogen activators for direct thrombolysis? Trends Pharmacol Sci 25 72.
18. K Ouriel, J Cynamon, FA Weaver, et al. (2005) A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 16 1075.
19. D Stewart, M Kong, V Novokhatny, et al. (2003) Distinct dose‐dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 101 3002.
20. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2 349.
21. The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 673.
22. CM O'Connor, R Meese, R Carney, et al. (1994) A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) I. J Am Coll Cardiol 23 11.
23. R Collins, R Peto, C Baigent and P Sleight (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336 847.
24. KW Mahaffey, CB Granger, R Collins, et al. (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77 551.
25. V Menon, RA Harrington, JS Hochman, et al. (2004) Thrombolysis and adjunctive therapy in acute myocardial infarction. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 549S.
26. L Wallentin, P Goldstein, PW Armstrong, et al. (2003) Efficacy and safety of tenecteplase in combination with the low‐molecular‐weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)‐3 PLUS randomized trial in acute myocardial infarction. Circulation 108 135.
27. Fibrinolytic Therapy Trialists Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 311.
28. ML Simoons, AP Maggioni, G Knatterud, et al. (1993) Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 342 1523.
29. The Continuous Infusion Versus Double‐Bolus Administration of Alteplase (COBALT) Investigators (1997) A comparison of continuous infusion of alteplase with double‐bolus administration for acute myocardial infarction. N Engl J Med 337 1124.
30. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337 1118.
31. CP Cannon, CH McCabe, TD Henry, et al. (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue‐type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23 993.
32. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90 1631.
33. EM Antman (1996) Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 94 911.
34. P Theroux, F Perez‐Villa, D Waters, et al. (1995) Randomized double‐blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct‐related artery in acute myocardial infarction. Circulation 98 2132.
35. HD White, PE Aylward, MJ Frey, et al. (1997) Randomized, double‐blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 96 2155.
36. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group (2000) Trial of abciximab with and without low‐dose reteplase for acute myocardial infarction. Circulation 101 2788.
37. EM Antman, RP Giugliano, CM Gibson, et al. (1999) Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 Trial. The TIMI 14 Investigators. Circulation 99 2720.
38. U Rosenschein, LA Rozenszajn, L Kraus, et al. (1991) Ultrasonic angioplasty in totally occluded peripheral arteries: Initial clinical, histological and angiographic results. Circulation 83 1976.
39. AV Alexandrov, CA Molina, JC Grotta, et al. (2004) Ultrasound‐enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 2170.
40. K Ouriel, FJ Veith and AA Sasahara (1998) A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 338 1105.
41. AJ Comerota, RC Throm, SD Mathias, et al. (2000) Catherter‐directed thrombolysis for iliofemoral deep venous thrombosis improves health‐related quality of life. J Vasc Surg 32 130.
42. K Ouriel, B Gray, DG Clair, et al. (2000) Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter‐directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 11 295.
43. A Furlan, R Higashida, L Wechsler, et al. (1999) Intra‐arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. JAMA 282 2003.
44. AK Jacobs (2003) Primary angioplasty for acute myocardial infarction: Is it worth the wait? N Engl J Med 349 798.
45. S Sherry, AP Fletcher and N Alkjaersig (1959) Fibrinolysis and fibrinolytic activity in man. Physiol Rev 39 343.
46. B Adelman, AD Michelson, J Loscalzo, et al. (1985) Plasmin effect on platelet glycoprotein IB–von Willebrand factor interactions. Blood 65 32.
47. MA Rudd, D George, P Amarante, et al. (1990) Temporal effect of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 67 1175.
48. The Urokinase Pulmonary Embolism Trial (1973) A national cooperative study. Circulation 47(suppl II), 1.
49. VJ Marder, RL Soulen, V Atichartakarn, et al. (1977) Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 89 1018.
50. AK Rao, C Pratt, A Berke, et al. (1988) Thrombolysis in MI (TIMI) Trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 1.
51. JM Gore, M Sloan, TR Price, et al. (1991) Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 83 448.
52. MM Bernardi, RM Califf, N Kleiman, et al. (1993) Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. Am J Cardiol 72 1121.
53. DC Stump, RM Califf, EJ Topol, et al. (1989) Pharmacodynamics of thrombolysis with recombinant tissue‐type plasminogen activator: Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 80 1222.
54. SE Carlson, MS Aldrich, HS Greenberg and EJ Topol (1988) Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment. Arch Neurol 45 1070.
55. SD Berkowitz, CB Granger, KS Pieper, et al. (1997) Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators. Circulation 95 2508.
56. CW White, JL Schwartz, DW Ferguson, et al. (1984) Systemic markers of fibrinolysis after unsuccessful intracoronary streptokinase thrombolysis for acute myocardial infarction: Does nonreperfusion indicate failure to achieve a systemic lytic state? Am J Cardiol 54 712.
57. CM Lawler, EG Bovill, DC Stump, et al. (1990) Fibrin fragment D‐dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 76 1341.
58. B Brenner, CW Francis, PG Fitzpatrick, et al. (1989) Relation of plasma D‐dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction. Am J Cardiol 63 1179.
59. Gruppo Italiano per lo Studio Della Streptochinase Nell'infarto Miocardico (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1 397.
60. KF Lee, J Mandell, JS Rankin, et al. (1988) Immediate versus delayed coronary grafting after streptokinase treatment: Post‐operative blood loss and clinical results. J Thorac Cardiovasc Surg 95 216.
61. TIMI Research Group (1988) Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute MI: TIMI IIA results. JAMA 260 2849.
62. RL Mentzer, AZ Budzynski and S Sherry (1986) High‐dose, brief‐duration intravenous infusion of streptokinase in acute myocardial infarction: Description of effects in the circulation. Am J Cardiol 57 1220.
63. J Owen, KD Friedman, BA Grossman, et al. (1987) Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest 79 1642.
64. B Nunn, R Esmail, R Fears, et al. (1987) Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans. Drugs Suppl 3 88.
65. SZ Goldhaber, J Heit, GVRK Sharma, et al. (1988) Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 2 293.
66. CW Francis, B Brenner, JP Leddy and VJ Marder (1991) Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 77 562.
67. Third International Study of Infarct Survival Collaborative Group (1992) ISIS‐3: A randomized comparison of streptokinase vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1 753.
68. GA Sicard, JJ Schier, WG Totty, et al. (1985) Thrombolytic therapy for acute arterial occlusion. J Vasc Surg 2 65.
69. EJ Immelman and PC Jeffery (1984) The post‐phlebitic syndrome: Pathophysiology, prevention and management. Clin Chest Med 5 537.
70. J Hirsh and J Hoak (1996) Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals. Circulation 93 2212.
71. CW Francis and VJ Marder (1991) Fibrinolytic therapy for venous thrombosis. Prog Cardiovasc Dis 34 193.
72. AGG Turpie, MN Levine, J Hirsh, et al. (1990) Tissue plasminogen activator vs heparin in DVT: Results of a randomized trial. Chest 97 172S.
73. Thrombolytic therapy in thrombosis (1980) A National Institutes of Health consensus development conference. Ann Intern Med 93 141.
74. J Schweizer, W Kirch, R Koch, et al. (2000) Short‐ and long‐term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol 36 1336.
75. CP Semba and MD Dake (1994) Iliofemoral deep venous thrombosis: Aggressive therapy with catheter‐directed thrombolysis. Radiology 191 487.
76. H Bjarnason, JR Kruse, DA Azinger, et al. (1997) Iliofemoral deep vein thrombosis: Safety and efficacy outcome during 5 years of catheter‐directed thrombolytic therapy. J Vasc Intervent Radiol 8 405.
77. MW Mewissen, GR Seabrook, MH Meissner, et al. (1999) Catheter‐directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology 211 39.
78. H Decousus, A Leizorovicz, F Parent, et al. (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 338 409.
79. JE Dalen and JS Alpert (1975) Natural history of pulmonary embolism. Prog Cardiovasc Dis 17 259.
80. SZ Goldhaber (1991) Thrombolysis for pulmonary embolism. Prog Cardiovasc Dis 34 113.
81. GV Sharma, ED Folland, KM McIntyre and AA Sasahara (2000) Long‐term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med 5 91.
82. N Meneveau, F Schiele, A Vuillemenot, et al. (1997) Streptokinase versus alteplase in massive pulmonary embolus: A randomized trial assessing right heart hemodynamics and pulmonary vascular obstruction. Eur Heart J 18 1141.
83. SZ Goldhaber, CM Kessler, JA Heit, et al. (1992) Recombinant tissue‐type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. J Am Coll Cardiol 20 24.
84. N Meneveau, F Schiele, D Metz, et al. (1998) Comparative efficacy of a two‐hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one‐year follow‐up. J Am Coll Cardiol 31 1057.
85. U Tebbe, A Graf, W Kamke, et al. (1999) Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 138 39.
86. M Verstraete, GAH Miller, H Bounameaux, et al. (1988) Intravenous and intrapulmonary recombinant tissue‐type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 77 353.
87. Urokinase Streptokinase Embolism Trial (1974) Phase 2 results: A cooperative study. JAMA 229 1606.
88. M Ruiz‐Bailen, E Aguayo‐de‐Hoyos, MC Serrano‐Corcoles, et al. (2001) Thrombolysis with recombinant tissue plasminogen activator during cardiopulmonary resuscitation in fulminant pulmonary embolism: A case series. Resuscitation 51 97.
89. Urokinase Pulmonary Embolism trial (1970) Phase 1 results: A cooperative study. JAMA 214 2163.
90. M Martin, W Schoop and E Zietler (1970) Streptokinase in chronic arterial occlusive disease. JAMA 211 1169.
91. A Amery, W Deloof, J Vermylen and M Verstraete (1970) Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. Br Med J 4 639.
92. CT Dotter, J Rosch and AJ Seaman (1974) Selective clot lysis with low‐dose streptokinase. Radiology 111 31.
93. H Hess, H Ingrisch, A Mietaschk, et al. (1982) Local low‐dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 307 1627.
94. GA Sicard, JJ Schier, WG Totty, et al. (1985) Thrombolytic therapy for acute arterial occlusion. J Vasc Surg 2 65.
95. K Ouriel, CK Shortell, JA De Weese, et al. (1994) A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 19 1021.
96. K Ouriel, FJ Veith and AA Sasahara Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators: (1998) A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 338 1105.
97. The STILE Investigators (1994) Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: The STILE trial. Ann Surg 220 251.
98. M Belkin, B Belkin, CA Bucknam, et al. (1986) Intra‐arterial fibrinolytic therapy: Efficacy of streptokinase vs. urokinase. Arch Surg 121 769.
99. K Ouriel, B Katzen, M Mewissen, et al. (2000) Reteplase in the treatment of peripheral arterial and venous occlusions: A pilot study. J Vasc Interv Radiol 11 849.
100. S Heymans, S Vanderschueren, R Verhaeqhe, et al. (2000) Outcome and one year follow‐up of intra‐arterial staphylokinase in 191 patients with peripheral arterial occlusion. Thromb Haemost 83 666.
101. MG Franzosi, E Santoro, C De Vita, et al. (1998) Ten‐year follow‐up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto‐1 study. The GISSI Investigators. Circulation 98 2659.
102. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group (1998) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2 349.
103. R Collins, R Peto, C Baigent and P Sleight (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336 847.
104. KW Mahaffey, CB Granger, R Collins, et al. (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77 551.
105. Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardioco (GISSI) (1990) GISSI‐2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336 65.
106. The International Study Group (1990) In‐hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336 71.
107. The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 673.
108. RW Smalling, C Bode, J Kalbfleisch, et al., RAPID Investigators (1995) More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91 2725.
109. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337 1118.
110. International Joint Efficacy Comparison of Thrombolytics (1995) Randomized, double‐blind comparison of reteplase double‐bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 346 329-336.
111. Assessment of the Safety and Efficacy of New Thrombolytic Investigators (1999) Single‐bolus tenecteplase compared with front‐loaded alteplase in acute myocardial infarction: The ASSENT‐2 double‐blind randomized trial. Lancet 354 716.
112. The InTIME‐II Investigators (2000) Intravenous NPA for the treatment of infarcting myocardium early: InTIME‐II, a double‐blind comparison of single‐bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 21 2005.
113. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)‐3 Investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT‐3 randomized trial in acute myocardial infarction. Lancet 358 605.
114. EJ Topol, The GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomized trial. Lancet 357 1905.
115. BK Metz, HD White, CB Granger, et al., Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO‐IIb) Investigators (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO‐IIb Trial. J Am Coll Cardiol 31 1493.
116. The National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 1581.
117. GA Donnan, SM Davis, BR Chambers, et al. (1996) Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 276 961.
118. W Hacke, M Kaste, C Fieschi, et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 1017.
119. WM Clark, S Wissman, GW Albers, et al. (1999) Recombinant tissue‐type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282 2019.
120. JM Wardlaw, G del Zoppo and T Yamaguchi (2000) Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev 2 CD000213.
121. JM Wardlaw, CP Warlow and C Counsell (1997) Systematic review of evidence of thrombolytic therapy for acute ischemic stroke. Lancet 350 607.
122. A Furlan, R Higashida, L Wechsler, et al. (1999) Intra‐arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. JAMA 282 2003.
123. CS Kase, AJ Furlan, L Wechsler, et al. (2001) Cerebral hemorrhage after intra‐arterial thrombolysis for ischemic stroke: The PROACT II trial. Neurology 57 1603.
124. AI Qureshi, Z Ali, MF Suri, et al. (2001) Intra‐arterial third‐generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 49 41.